Back grey_arrow_rt.gif
 
 
Ardea HIV NNRTI May Treat Gout to An HIV Drug. Or A Gout Drug? Or Both. . .
 
 
  We get a lot of surprises in this business, most of them not so good. That's understandable, since there are lot more ways for drugs and their mechanisms to go wrong than there are for them to go right. But once in a while, you do see something that's unexpectedly good news.
 
That may be what's happened to a small San Diego outfit, Ardea. As Xconomy details, the company (formed out of the remnants of IntraBiotics and Valeant) was testing an HIV compound in the clinic when they noticed significant declines in blood levels of uric acid.
 
That rang a bell: something that decreases uric acid levels would be useful for gout, and there's only been one new gout drug approved in the last 40 years. Follow-up work showed that the effect seemed to be coming from a metabolite of the original drug, and thanks to the HIV trial data, they already had good hopes for that compound's safety. The new compound, RDEA594, has made it through Phase I and is headed for Phase II, and the trials look to be manageable affairs that the company can afford to run. The market is there: more people have gout in the US than are HIV-positive (although the two diseases clearly aren't comparable in other respects!). But the state of HIV research now means, weirdly, that the serious medical needs in that population are actually being met more completely than those in many other disease areas. (Ardea's HIV compound is progressing as well).
 
Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information
Mon.. April 13, 2009; Posted: 08:30 AM
 
SAN DIEGO, Apr 13, 2009 (BUSINESS WIRE) -- -- Ardea Biosciences, Inc. (Nasdaq:RDEA), a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer and inflammatory diseases, today announced event participants and webcast information for its Investor and Analyst Event on Monday, April 20, 2009 from 5:00 p.m. to 7:00 p.m. Eastern Daylight Time in New York City.
 
Ardea will present results from its recently completed Phase 1 studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and Phase 2a study of RDEA806, RDEA594's prodrug, in patients with gout. Plans for the Phase 2 development program with RDEA594, scheduled to start in the second quarter of 2009, will also be presented. Panel discussion participants are expected to include Ardea management and key opinion leaders in the field of gout and hyperuricemia, including:
 
Mark C. Genovese, MD Associate Professor of Medicine and Co-Chief of the Division of Immunology and Rheumatology Stanford University Medical Center Palo Alto, CA (via video conference)
 
and
 
Fernando Perez-Ruiz, MD, PhD Assistant Head of the Rheumatology Division Hospital de Cruces Vizcaya, Spain
 
To access the webcast, please log onto Ardea's website at www.ardeabio.com and click on the Investors Center section approximately 10 minutes prior to the start of the webcast to allow for any software downloads that may be necessary. An archived recording of the event will be available on Ardea's website for one month.
 
About Ardea Biosciences, Inc.
 
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development based on a plasma half-life of greater than 40 hours. RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is being evaluated in Phase 1 clinical trials. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1/2 study in combination with sorafenib (Nexavar(R), Onyx Pharmaceuticals, Bayer HealthCare) and as a single agent in a Phase 1 study, both in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.
 
SOURCE: Ardea Biosciences, Inc.
 
Ardea Biosciences, Inc.
John Beck
858-652-6523
jbeck@ardeabio.com
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org